Items which should not routinely be prescribed in primary care - glucosamine and chondroitin by all Sub-ICB Locations
Why it matters:
Glucosamine and chondroitin are nutraceuticals used to improve pain associated with osteoarthritis. The BNF states: 'The mechanism of action is not understood and there is limited evidence to show it is effective'.
NICE guidance on osteoarthritis care and management has the following 'do not do' recommendation: Do not offer glucosamine or chondroitin products for the management of osteoarthritis.
Due to the recommendation from NICE and the lack of evidence as advised by the BNF, the joint clinical working group considered glucosamine and chondroitin suitable for inclusion in this guidance.
NHS England recommend that GPs:
- Do not initiate.
- Deprescribe in patients currently prescribed this medicine.
Description: Cost of glucosamine and chondroitin per 1000 patients
Performance: Loading...
Explore:
Tagged as: Cost Saving, Efficacy, NHS England - items which should not routinely be prescribed in primary care, NICE (or browse all measures)
Sub-ICB Locations are ordered by mean percentile over the past six months. Each chart shows the results for the individual Sub-ICB Location, plus deciles across all Sub-ICB Locations in the NHS in England.
View measure for NHS England combined →
Fetching data...